Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind trial of TQ05105 versus hydroxyurea in intermediate-2 or high-risk myelofibrosis
CTR20212571Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rovadicitinib in myelofibrosis (MF), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Oct 2021; status: completed.
02
Drugs
rovadicitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20212571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212571.